| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DNAH6 |
| Uniprot No | Q9C0G6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-408aa |
| 氨基酸序列 | MTYTEQASKRHYCMRLTCFIRLNDYLIENTMHILTVNAVNSLLNHLTDKLKRTPSADVIQKWITEEKPEVPDKKGTLMVEKQEEDESLIPMFLTELMLTVQSLLFEPSLEDFLDGILGAVNHCQNTVLSVPNLVPDSYFDAFTSPYINNKLEGKTCGTGPSLAAVFEDDKNFHTIISQIKETIQAAFESARIYAATFEKFQIFFKENESLDLQALKLQEPDINFFSEQLEKYHKQHKDAVALRPTRNVGLLLIDTRLLREKLIPSPLRCLEVLNFMLPRQSKKKVDAIIFEAQDAEYKLEFVPTTTTEYVHSLLFLDEIQERIESLEDEGNIVTQMYKLMEQYQVPTPPEDFAVFATMKPSIVAVRNAIDKSVGDRESSIKQFCVHLGSDLEELNNEVNEVKLQAQVS |
| 分子量 | 44.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
由于文献数据库访问受限，我无法提供真实存在的参考文献，但可为您模拟示例格式。以下是基于DNAH6已知生物学特性的假设性文献示例：
1. **《重组人DNAH6蛋白的表达与功能研究》**
- 作者：Zhang L et al.
- 摘要：本研究成功在大肠杆菌中表达并纯化了重组人DNAH6蛋白，验证了其ATP酶活性，并发现其在体外微管结合实验中调控纤毛运动相关分子机制。
2. **《DNAH6突变体导致原发性纤毛运动障碍的分子机制》**
- 作者：Smith K et al.
- 摘要：通过构建重组DNAH6致病突变体蛋白，揭示其与动力蛋白复合体结合能力下降，导致呼吸道上皮纤毛运动缺陷，与新生儿呼吸道疾病相关。
3. **《重组DNAH6的结构解析及分子动力学模拟》**
- 作者：Watanabe M et al.
- 摘要：利用冷冻电镜技术解析重组DNAH6的3D结构，结合分子动力学模拟阐明其ATP水解结构域的动态变化，为靶向药物设计提供依据。
**建议**：如需真实文献，可访问PubMed(https://pubmed.ncbi.nlm.nih.gov)检索关键词 "recombinant human DNAH6" 或 "DNAH6 protein function"。
Recombinant human DNAH6 protein is a genetically engineered form of the dynein axonemal heavy chain 6 protein, a member of the dynein motor protein family. DNAH6 is primarily localized in the axoneme of motile cilia and flagella, where it contributes to microtubule sliding and coordinated ciliary/flagellar movement. This protein plays critical roles in physiological processes such as respiratory mucociliary clearance, cerebrospinal fluid flow, and sperm motility. Dysregulation or mutations in DNAH6 have been associated with primary ciliary dyskinesia (PCD), a genetic disorder characterized by chronic respiratory infections, infertility, and laterality defects, as well as potential links to certain cancers.
The recombinant form is produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to enable detailed study of its molecular functions. Its production allows researchers to investigate DNAH6's ATPase activity, microtubule-binding properties, and interactions with other axonemal components. Recombinant DNAH6 serves as a vital tool for developing disease models, screening therapeutic compounds targeting ciliary defects, and advancing gene therapy approaches. Studies using this recombinant protein have improved understanding of cilia-associated signaling pathways and structural abnormalities in ciliopathies. Ongoing research focuses on clarifying its tissue-specific isoforms and post-translational modifications that may influence ciliary beat patterns and cellular motility.
×
